Neurol. praxi. 2017;18(5):306-308 | DOI: 10.36290/neu.2017.102

Myasthenia gravis and anesthesia

MUDr. Stanislav Voháňka, CSc., MBA, MUDr. Magda Horáková
Neuromuskulární centrum, Neurologická klinika LF MU a FN, Brno

Myasthenia gravis is an autoimmune disorder of neuromuscular transmission. There are many drugs frequently used in anesthesiologywhich interfere significantly with this disease. The most important are peripheral blocking agents and potent inhaledanesthetic agents. Patients suffering from myasthenia reveal modified sensitivity to these drugs, esp. to the peripheral blockingagents. Regional methods of the anesthesia or combination of both are preferred. Postoperative management is based on thecareful monitoration of patients until full recovery is reached. In patient with myasthenia gravis there is no risk of malignanthyperthermia.

Keywords: neuromuscular junction, myasthenia gravis, neuromuscular blocking agents, cholinesterase inhibitors

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Voháňka S, Horáková M. Myasthenia gravis and anesthesia. Neurol. praxi. 2017;18(5):306-308. doi: 10.36290/neu.2017.102.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abel M, Eisenkraft JB. Anesthetic implications of myasthenia gravis. Mt. Sinai J. Med. N. Y. 2002; 69: 31-37.
    2. Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 2006; 13: 1006-1010. Go to original source...
    3. Batistaki C, Tentes P, Deligiannidi P, Karakosta A, Florou P, Kostopanagiotou G. Residual neuromuscular blockade in a real life clinical setting. Correlation with sugammadex or neostigmine administration. Minerva Anestesiol. 2015.
    4. Bowie RA. Myasthenia gravis unmasked by neuromuscular blockade. Br. J. Anaesth. 2002; 88: 153-154. Go to PubMed...
    5. Brambrink AM, Kirsch JR. Perioperative care of patients with neuromuscular disease and dysfunction. Anesthesiol. Clin. 2007; 25: 483-509. Go to original source... Go to PubMed...
    6. Dunsire MF, Clarke SG, Stedmon JJ. Undiagnosed myasthenia gravis unmasked by neuromuscular blockade. Br. J. Anaesth. 2001; 86: 727-730. Go to original source... Go to PubMed...
    7. Eisenkraft JB, Book WJ, Mann SM, Papatestas AE, Hubbard M. Resistance to succinylcholine in myasthenia gravis: a dose-response study. Anesthesiology 1988; 69: 760-763. Go to PubMed...
    8. Finsterer J, Stöllberger C. Myocarditis in myasthenia gravis. Int. J. Cardiol. 2016; 209: 342-343. Go to original source... Go to PubMed...
    9. Hofstad H, Ohm OJ, M?rk SJ, Aarli JA. Heart disease in myasthenia gravis. Acta Neurol. Scand. 1984; 70: 176-184. Go to original source... Go to PubMed...
    10. Joudinaud TM, Fadel E, Thomas-de-Montpreville V, Mussot S, Flecher EM, Dartevelle PG. Fatal giant cell myocarditis after thymoma resection in myasthenia gravis. J. Thorac. Cardiovasc. Surg. 2006; 131: 494-495. Go to original source... Go to PubMed...
    11. Kato T, Hirose S, Kumagai S, Ozaki A, Matsumoto S, Inoko M. Electrocardiography as the First Step for the Further Examination of Cardiac Involvement in Myasthenia Gravis. BioMed Res. Int. 2016; http://dx.doi.org/10.1155/2016/8058946. Go to original source... Go to PubMed...
    12. Marsh S, Pittard A. Neuromuscular disorders and anaesthesia. Part 2: specific neuromuscular disorders. Contin. Educ. Anaesth. Crit. Care Pain 2011; 11: 119-123. Go to original source...
    13. Racca F, Mongini T, Wolfler A, Vianello A, Cutrera R, Del Sorbo L, Capello EC, Gregoretti C, Massa R, De Luca D, Conti G, Tegazzin V, Toscano A, Ranieri VM. Recommendations for anesthesia and perioperative management of patients with neuromuscular disorders. Minerva Anestesiol. 2013; 79: 419-433. Go to PubMed...
    14. Racca TM. Recommendations for anesthesia and perioperative management of patients with neuromuscular disorders. Minerva Anestesiol. 2013; 79.
    15. Rangasamy V, Kumar K, Rai A, Baidya DK. Sevoflurane and thoracic epidural anesthesia for trans-sternal thymectomy in a child with juvenile myasthenia gravis. J. Anaesthesiol. Clin. Pharmacol. 2014; 30: 276-278. Go to original source...
    16. Romero A, Joshi GP. Neuromuscular disease and anesthesia. Muscle Nerve 2013; 48: 451-460. Go to original source... Go to PubMed...
    17. Shousha AA, Sanfilippo M, Sabba A, Pinchera P. Sugammadex and reversal of neuromuscular block in adult patient with Duchenne muscular dystrophy. Case Rep. Anesthesiol. 2014: 1-3. Go to original source... Go to PubMed...
    18. Voháňka S. Léky a nervosvalový přenos. Neurol. praxi 2017; 18: 11-14. Go to original source...
    19. Werner Klingler FL-H. Complications of anaesthesia in neuromuscular disorders. Neuromuscul. Disord. NMD 2005; 15: 195-206. Go to original source... Go to PubMed...
    20. White MC, Stoddart PA. Anesthesia for thymectomy in children with myasthenia gravis. Paediatr. Anaesth. 2004; 14: 625-635. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.